Tuberous Sclerosis and Renal Involvement

Case Report

Tuberous Sclerosis Presented With Polycystic Kidney Disease and Acute Renal Failure

Ahmet Engin Atay MD1, Suleyman Ozupekce MD2, Halit Akbas PhD3, Murat Acar MD4, Semir Pasa MD5, Memduh Oruc MD5

Abstract
Tuberous sclerosis complex (TSC) is an autosomal dominant disorder characterized by hamartomatous involvement of multiple organs such as the skin, central nervous system, kidneys, lungs, and heart. A linkage has been found with a locus on the long arm of chromosome 9 (9q34) and with a locus on the short arm of chromosome 16 (16p13). TSC has a birth incidence of 1/6000. Children with TSC are almost universally born with normal kidneys, but cystic disease and angiomyolipomas develop with increasing age. Angiomyolipomas, renal cysts, and renal cell carcinoma are classical features of renal involvement in TSC. Renal complications are the most common cause of death in adult TSC patients, thus renal involvement has a crucial importance on the course of this disease. We present a 27-year-old patient previously diagnosed as tuberous sclerosis complex and referred with acute renal failure and polycystic kidney disease.

Keywords: Acute renal failure, polycystic kidney disease, tuberous sclerosis


Introduction

Tuberous sclerosis complex (TSC), a genetic tumor predisposition syndrome, has a birth incidence of 1/6000 with wide-ranging organ system involvement that includes central nervous system, skin, renal, and lung manifestations.1 Patients with TSC almost entirely experience renal complications in different stages of the disease and at different severities. Renal angiomyolipomas, cysts, and less frequently renal cell carcinoma are typical features of renal involvement in TSC. Adjacent TSC and PKD1 genes are associated with severe and early onset polycystic phenotype, and account for 2% of TSC patients.2 We report the case of a young male with tuberous sclerosis complex who referred to our outpatient clinic with acute renal failure due to dehydration and possible antiepileptic medication-related renal cell injury.

Case Report

A 27-year-old male patient referred to our outpatient clinic with complaints of nausea, vomiting, fatigue, and intermittent left flank pain. The diagnosis of tuberous sclerosis had been confirmed by clinical and genetic examinations at the age of three years. Molecular analysis revealed a mutation in the TSC-2 gene that localized on the short arm of chromosome 16 (16p13). The presenting symptom was a seizure, and thus antiepileptic therapy was initiated. He had a history of three seizures, all at different ages. Although no epileptic attack had been observed since the age of ten, the patient continued with prophylactic anticonvulsant therapy. He had characteristic facial angiofibromas and a shagreen patch (Figure 1). Previous ultrasonographic examinations indicated multiple angiomyolipomas, less than 2 cm in diameter in both kidneys. Nausea and vomiting persisted for two days and gradually increased. He was apparently hypotensive (blood pressure: 70/40 mmHg) and tachycardic (pulse: 116/minute). A mild increase in serum urea and creatinine levels were determined and supportive therapy was initiated. Biochemical abnormalities resolved and symptoms improved on the second day of hospitalization.

The patient underwent a detailed multidisciplinary clinical assessment, however, no apparent abnormality was observed during the respiratory function test, echocardiographic, and thoracic tomographic examinations. The glomerular filtration rate was estimated by 24-hour urine creatinine clearance and Cockcroft and Gault formula. A cranial MR imaging study indicated a tuberous formation in the left supratentorial area (Figure 2). Abdominal ultrasonographic examination pointed out renal angiomyolipoma and cyst formation. Both were confirmed by abdominal tomographic examination. Cysts smaller than 1 cm in size, undetectable by ultrasonography, were also observed (Figure 3 and 4). Regular, frequent follow-ups of at least three month intervals were suggested to determine the complications of the disease in its earlier stages. Other family members underwent to molecular and clinical evaluations for the possible presence of TSC.

Discussion

Renal involvement has a vital importance on the course of TSC because of the relentless progression of chronic kidney disease (CKD). Patients with TSC also are at risk for acute kidney injury that can include the use of anticonvulsant and nonsteroidal anti-inflammatory medications as well as rhabdomyolysis and hypoxia, which is induced by prolonged seizures.3 More than half of the kidney function must be lost before a rise in serum creatinine is detectable.4 Renal causes of death were second only to the central
nervous system, however recently renal complications have been considered as the leading causes of death in patients with TSC.4,5

Angiomyolipomas are the prototype of a family of lesions called perivascular epitheloid cell tumors (PEComas). These lesions generally exhibit immunoreactivity for both melanocytic markers as detected by HMB-45 and smooth-muscle markers such as actin and desmin.1 Angiomyolipomas significantly affect the outcome of TSC because they can invade adjacent normal renal parenchyma, leading to chronic kidney disease. In addition, they can cause aneurysms that may rupture.6 The risk of hemorrhage from renal angiomyolipomas in patients with TSC varies between 25% and 50% and is related to aneurysm size, with the greatest risk being in aneurysms > 5 mm.7,8 Ultrasound has been the predominant imaging modality to screen for angiomyolipomas. Currently no imaging methods distinguish between fat-poor angiomyolipomas and carcinomas. Recently the growth rate has been introduced as a possible method to distinguish renal cell carcinoma (RCC) from angiomyolipoma.9 HMB-45 and melanin A are beneficial for differentiating RCC from angiomyolipoma. The incidence of RCC in patients with TSC is similar to that in the general population, with a lifetime risk of 2% to 3%; however, cancer is diagnosed at a younger age in patients with TSC.10

The responsible locus of TSC2 and PKD1 lie adjacent to each other at chromosome 16p13.3, suggesting a role for PKD1 in the etiology of renal cystic disease in TSC. Radiologically cystic diseases resemble autosomal dominant polycystic kidney disease (ADPKD).11 Renal cystic disease can also be microcystic and undetectable by imaging studies.12 Patients with renal cystic disease have a significant risk for nephrolithiasis related to distal tubular dysfunction. This leads to hypocitraturia and hypertension, which responds very well to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.6

Rakowski et al reported that percentages of renal manifestations observed in patients with tuberous sclerosis complex are as follows; angiomyolipomas are 85.4%, cysts are 44.8%, and renal cell carcinomas are 4.2%.13 Both angiomyolipomas and cysts were significantly more common and more numerous in TSC2 than in TSC1. AML was significantly more common in females than in males.13 The frequency and number of renal lesions positively correlated with age,6,14 with an average age at onset of AML of 7.2 years; the age of onset for cysts is 9 years.15,16 However, they may be present as early as the first year of life or even at birth.15 Although optimal surveillance protocols for renal imaging in TSC are not established, Rakowski et al. have recommended a baseline renal ultrasound (USG) before 5 years of age and a repeat every 2–3 years, if results are normal. They recommended yearly ultrasound follow-ups, if angiomyolipomas or cysts were observed. If RCC was suspected, an MRI for re-evaluation and follow-up imaging at six-month intervals was required.13 The TSC Consensus Conference of 1998 recommended renal ultrasonography every 1–3 years to assess the development or progression of angiomyolipomas.17 The purpose of serial imaging was to lower the renal complications of TSC, such as aneurysm, rupture, and hemorrhage.18 Regular follow-up and appropriate therapy are essential to determine renal complications of TSC in the earlier stages and...
to overcome the preventable complications including acute renal failure.

References


Sunrise, Taleqan, near Tehran (Photo by M.H. Azizi MD, 2011)